Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Equity (2017 - 2025)

Historic Return on Equity for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 0.5%.

  • Adma Biologics' Return on Equity rose 1800.0% to 0.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.5%, marking a year-over-year increase of 1800.0%. This contributed to the annual value of 0.82% for FY2024, which is 10100.0% up from last year.
  • As of Q3 2025, Adma Biologics' Return on Equity stood at 0.5%, which was up 1800.0% from 0.54% recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Return on Equity peaked at 0.68% during Q4 2024, and registered a low of 0.75% during Q1 2021.
  • In the last 5 years, Adma Biologics' Return on Equity had a median value of 0.27% in 2023 and averaged 0.16%.
  • As far as peak fluctuations go, Adma Biologics' Return on Equity soared by 800bps in 2021, and later skyrocketed by 8800bps in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' Return on Equity stood at 0.59% in 2021, then increased by 21bps to 0.46% in 2022, then skyrocketed by 58bps to 0.2% in 2023, then surged by 445bps to 0.68% in 2024, then decreased by -26bps to 0.5% in 2025.
  • Its last three reported values are 0.5% in Q3 2025, 0.54% for Q2 2025, and 0.57% during Q1 2025.